Clinical trials
Phase 2 Lymphoma, Large B-Cell, Diffuse trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Active, not recruiting | 6 |
| Terminated | 3 |
| Unknown status | 2 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Celgene | 2 |
| University College, London | 2 |
| University Hospital Southampton NHS Foundation Trust | 2 |
| University of Birmingham | 2 |
| AstraZeneca | 1 |
| Bayer | 1 |
| Calithera Biosciences, Inc | 1 |
| Cancer Research UK | 1 |
| Cellectar Biosciences, Inc. | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, Large B-Cell, Diffuse | 28 |
| Lymphoma | 11 |
| Lymphoma, Non-Hodgkin | 7 |
| Recurrence | 6 |
| Lymphoma, B-Cell | 3 |
| Lymphoma, Follicular | 3 |
| Burkitt Lymphoma | 2 |
| Lymphoma, B-Cell, Marginal Zone | 2 |
| Lymphoma, Mantle-Cell | 2 |
| Blood Protein Disorders | 1 |
Trials
Showing 1 to 25 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.